GIP; GLP-1 and glucagon receptor tri-agonist
Retatrutide 4 mg subcutaneous once weekly
RETA_SC_4MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.27 (0.25 to 5.17) | 0.41 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.94 (1.03 to 7.94) | 0.46 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.55 (0.04 to 3.39) | 0.82 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.57 (1.00 to 12.20) | 0.23 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -10.94 (-16.13 to -3.29) | 0.79 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -13.96 (-20.16 to -3.82) | 0.49 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.67 (0.10 to 3.71) | 0.64 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.38 (1.06 to 5.70) | 0.68 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.47 (1.15 to 21.20) | 0.48 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.02 (0.35 to 2.95) | 0.74 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.70 (0.70 to 11.83) | 0.39 |